• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is First MRD-Based CELMoD Approval in Myeloma Altering The Investment Case For Bristol Myers Squibb (BMY)?

    Simply Wall St·08/23/2026 02:24:08
    語音播報
    • Earlier this month, Bristol Myers Squibb received FDA accelerated approval for ZENBEXUS (iberdomide) plus daratumumab and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least one prior therapy.
    • This marks the first FDA-approved cereblon-modulating protein degrader and the first multiple myeloma approval based on minimal residual disease-negative complete response, highlighting a new regulatory path for BMS’s oncology portfolio.
    • We’ll now examine how this first-in-class CELMoD approval based on MRD-negative complete response reshapes Bristol Myers Squibb’s broader investment narrative.

    Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.

    Bristol-Myers Squibb Investment Narrative Recap

    To own Bristol Myers Squibb, you need to believe its next wave of oncology and immunology drugs can gradually replace revenue at risk from upcoming patent expirations. The ZENBEXUS accelerated approval strengthens the case that its CELMoD platform can contribute to that transition, but because it is conditional on confirmatory data and safety management, it does not materially change the near term risk that setbacks in key late stage programs could leave the company more exposed to its patent cliffs.

    The ZENBEXUS news ties directly into Bristol Myers Squibb’s broader oncology push and recent investments in innovation, such as the new US$2.3 billion, multi modal manufacturing campus in Houston. That facility is designed to support a wide range of modalities, including complex oncology products, and helps frame iberdomide’s approval as part of a larger effort to sustain the portfolio beyond current blockbusters, even as pricing pressure and loss of exclusivity remain central concerns.

    Yet while ZENBEXUS offers a fresh proof point for the pipeline, investors should also be aware that...

    Read the full narrative on Bristol-Myers Squibb (it's free!)

    Bristol-Myers Squibb’s narrative projects $40.1 billion revenue and $8.6 billion earnings by 2029. This implies a 6.2% yearly revenue decline but an earnings increase of about $1.3 billion from $7.3 billion today.

    Uncover how Bristol-Myers Squibb's forecasts yield a $62.96 fair value, a 6% downside to its current price.

    Exploring Other Perspectives

    BMY 1-Year Stock Price Chart
    BMY 1-Year Stock Price Chart

    Some of the lowest estimate analysts were already expecting Bristol Myers Squibb’s revenue to fall to about US$36.8 billion and earnings to drop to roughly US$4.7 billion, so compared with the baseline view that focuses on pipeline offsets to patent risk, their narrative is much more pessimistic and ZENBEXUS could be one of the events that ultimately challenges or reinforces those assumptions over time.

    Explore 6 other fair value estimates on Bristol-Myers Squibb - why the stock might be worth as much as 77% more than the current price!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Contemplating Other Strategies?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.